RxDoctor Payments Data

Behzad Kermani, MD

Internal Medicine · Las Vegas, NVNPI 1548208051

Payments from drug & device makers

$836in general payments, 2019–2025

Across 31 payments — averaging $26.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$158
  • Johnson & Johnson$148
  • Pfizer$114
  • Bayer$82
  • AbbVie$63
  • Novo Nordisk$52
  • plus $220 from 6 others

What the payments were for

  • Food & beverage$836100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$836 in reported general payments places this provider in the 70th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$76,259
Medicare patients
162
Services billed
774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$84,145
OzempicSemaglutide20$46,258
TradjentaLinagliptin27$28,932
MounjaroTirzepatide24$26,573
JardianceEmpagliflozin17$25,476
LinzessLinaclotide25$24,892
Lantus SolostarInsulin Glargine,hum.Rec.Anlog54$6,432
Losartan Potassium349$3,148
Atorvastatin Calcium306$2,724
Albuterol Sulfate HfaAlbuterol Sulfate67$2,075
Metformin Hcl292$1,897
Levothyroxine Sodium167$1,636
Simvastatin202$1,604
Lisinopril269$1,516
Alendronate Sodium194$1,449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$114$84,14574 claims
Boehringer IngelheimTradjenta, Jardiance$158$54,40844 claims
Novo NordiskOzempic$52$46,25820 claims
Lilly USA, LLCMounjaro$38$26,57324 claims
AbbVieLinzess$63$24,89225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →